Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXM1 | Q08050 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 7/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ESRRA | P11474 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492772 | 1.00 | FOXM1 (0.47) | FOXM1PIM1PIM2CISD1TTR | |
| SCHEMBL5484278 | 1.00 | FOXM1 (0.47) | FOXM1PIM1PIM2CISD1TTR | |
| SCHEMBL7463194 | 0.93 | PIM1 (0.47) | FOXM1PIM1PIM2CISD1TTR | |
| SCHEMBL7463186 | 0.93 | PIM1 (0.47) | FOXM1PIM1PIM2CISD1TTR | |
| SCHEMBL5491435 | 0.88 | ESRRA (0.48) | PIM1PIM2CISD1TTRHPGD | |
| SCHEMBL14492771 | 0.88 | ESRRA (0.48) | PIM1PIM2CISD1TTRHPGD | |
| SCHEMBL5491428 | 0.88 | ESRRA (0.48) | PIM1PIM2CISD1TTRHPGD | |
| SCHEMBL14492775 | 0.87 | IGF1R (0.52) | PIM1PIM2CISD1TTRIGF1R | |
| SCHEMBL5491266 | 0.87 | IGF1R (0.52) | PIM1PIM2CISD1TTRIGF1R | |
| SCHEMBL5491261 | 0.87 | IGF1R (0.52) | PIM1PIM2CISD1TTRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | claimed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6974826-B2 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1593677-A2 | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes | Incyte San Diego Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. | 2005-03-31 | — | — | US | disclosed |
| US-6765013-B2 | ANTIPROLIFERATIVE AGENTS FOR TREATING ADIPOCYTE DIFFERENTIATION, CANCER, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CROHN'S DISEASE OR INFLAMMATORY BOWEL DISEASE | INCYTE SAN DIEGO | 2004-07-20 | — | — | US | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | FOXM1 2022/4885PIM1 2383/4885PIM2 1465/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | FOXM1 1563/4885PIM1 2030/4885PIM2 1205/4885 |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, GPR119, IL2 | FOXM1 2001/4885PIM1 636/4885PIM2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.